Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q1 2010 Revenues Jump 19 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Thursday that its first-quarter 2010 revenues increased 19 percent, led by a 36 percent jump in revenues for its Enzo Clinical Labs division.

The New York-based firm brought in total revenues of $25.2 million for the three-month period ended Oct. 31, 2009, compared to $21.1 million for the first quarter of 2009. Revenues for its Enzo Life Sciences division increased around 16 percent, with product revenues increasing to $10.7 million from $10 million year over year, and royalty and license fees increasing to $3.3 million from $2.9 million.

Assay Designs, a reagent kit maker that Enzo acquired earlier this year for around $12.2 million, contributed revenues of $2.7 million for the quarter.

Enzo Clinical Labs had revenues of $11.1 million for the quarter, up from $8.2 million in the comparable period of fiscal 2009.

Enzo Biochem's net loss dropped sharply to $1.8 million, or $.03 per share, from $6.4 million, or $.16 per share.

The firm finished the quarter with $46.4 million in cash, cash equivalents, and short-term investments.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.